Literature DB >> 22475910

Conjunctival lymphoma can be detected by FDG PET.

Toshihiko Matsuo1, Kouichi Ichimura, Takehiro Tanaka, Mitsumasa Kaji.   

Abstract

Four consecutive patients presented with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the conjunctiva. After the initial resection, long-term follow-up without additional therapy showed the clinical relapse. Fluorodeoxyglucose positron emission tomography fused with computed tomography (PET/CT) showed abnormal uptake in the conjunctival relapsed lesions, which were, on reresection, again proven as MALT lymphoma. Small and thin lesions of MALT lymphoma in the conjunctiva can be detected by fluorodeoxyglucose PET/CT. The resolution of PET/CT, delineated in this study, could be applied to the other areas of the body to achieve more accurate staging of lymphoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22475910     DOI: 10.1097/RLU.0b013e31823ea96d

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

1.  The role of 18F-FDG PET/CT in diagnosis and treatment evaluation for ocular adnexal mucosa-associated lymphoid tissue lymphoma.

Authors:  Weifang Wang; Xiaochen Ni; Tianci Tang; Jie Wang; Yi Li; Xinmao Song
Journal:  Br J Radiol       Date:  2021-12-17       Impact factor: 3.039

Review 2.  Conjunctival Lymphoma.

Authors:  Lindsay A McGrath; David A Ryan; Sunil K Warrier; Sarah E Coupland; William J Glasson
Journal:  Eye (Lond)       Date:  2022-07-26       Impact factor: 4.456

3.  Value of positron emission tomography/computed tomography in diagnosis and staging of primary ocular and orbital tumors.

Authors:  Ka-Hoi Hui; Margaret L Pfeiffer; Bita Esmaeli
Journal:  Saudi J Ophthalmol       Date:  2012-10

4.  Conjunctival MALT lymphoma: utility of FDG PET/CT for diagnosis, staging, and evaluation of treatment response.

Authors:  Asmaa Sallak; Florent L Besson; Anastasia Pomoni; Alexandre Christinat; Marcel Adler; Jean-Philippe Aegerter; Christophe Nguyen; Laurence de Leval; Valérie Frossard; John O Prior
Journal:  Clin Nucl Med       Date:  2014-03       Impact factor: 7.794

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.